Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
11.61
-0.88 (-7.05%)
At close: Jun 26, 2026, 4:00 PM EDT
11.85
+0.24 (2.07%)
After-hours: Jun 26, 2026, 7:52 PM EDT
Lyell Immunopharma Revenue
Lyell Immunopharma had revenue of $2.00K in the quarter ending March 31, 2026, a decrease of -71.43%. This brings the company's revenue in the last twelve months to $31.00K, down -52.31% year-over-year. In the year 2025, Lyell Immunopharma had annual revenue of $36.00K, down -40.98%.
Revenue (ttm)
$31.00K
Revenue Growth
-52.31%
P/S Ratio
8,738.99
Revenue / Employee
$193
Employees
161
Market Cap
270.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.00K | -25.00K | -40.98% |
| Dec 31, 2024 | 61.00K | -69.00K | -53.08% |
| Dec 31, 2023 | 130.00K | -84.55M | -99.85% |
| Dec 31, 2022 | 84.68M | 74.03M | 695.15% |
| Dec 31, 2021 | 10.65M | 2.89M | 37.31% |
| Dec 31, 2020 | 7.76M | 7.10M | 1,080.52% |
| Dec 31, 2019 | 657.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Bicycle Therapeutics | 63.50M |
| Invivyd | 55.87M |
| Zentalis Pharmaceuticals | 26.87M |
| Adagene | 7.67M |
| Entrada Therapeutics | 5.74M |
| Armata Pharmaceuticals | 5.20M |
| Cartesian Therapeutics | 1.78M |
LYEL News
- 2 days ago - Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 15 days ago - Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress - GlobeNewsWire
- 17 days ago - Lyell Immunopharma Transcript: AGM 2026 - Transcripts
- 19 days ago - Lyell Immunopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 19 days ago - Lyell Immunopharma provides update on safety profile of LYL273 - TheFly
- 19 days ago - Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion - GlobeNewsWire
- 23 days ago - Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress - GlobeNewsWire
- 26 days ago - Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 - GlobeNewsWire